fda on tirzepatide Diabetes Drug - Gets Approval for Weight Loss Warning: Risks of Non-FDA Approved

This echoes the clinical practice already emerging with semaglutide and tirzepatide, where some prescribers step patients down after target weight is achieved

The Medicare GLP-1 Effect: How Coverage Expansion Is Rewriting Pharma Media Strategy The expansion of Medicare coverage for GLP-1 therapies represents one of the biggest shifts in healthcare marketing and pharmaceutical commercialization in recent years

The excessive infiltration of SMs into synovia causes articular immune dysfunction, accelerates the progression of synovitis, and leads to osteoclast activation and ultimate bone erosion and joint destruction 7,8

Baranauskaite A, Raffayov H, Kungurov NV, et al

Your healthcare provider can help evaluate whether adjusting your dosage might help